Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis

C. Lange; W. A. Alghamdi; M. H. Al-Shaer; S. Brighenti; A. H. Diacon; A. R. DiNardo; H. P. Grobbel; M. I. Gröschel; F. von Groote-Bidlingmaier; M. Hauptmann; J. Heyckendorf; N. Köhler; T. A. Kohl; M. Merker; S. Niemann; C. A. Peloquin; M. Reimann; U. E. Schaible; D. Schaub; V. Schleusener; T. Thye; T. Schön

doi:10.1111/joim.12780

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis

C. Lange^*, W. A. Alghamdi, M. H. Al-Shaer, S. Brighenti, A. H. Diacon, A. R. DiNardo, H. P. Grobbel, M. I. Gröschel, F. von Groote-Bidlingmaier, M. Hauptmann, J. Heyckendorf, N. Köhler, T. A. Kohl, M. Merker, S. Niemann, C. A. Peloquin, M. Reimann, U. E. Schaible, D. Schaub, V. SchleusenerT. Thye, T. Schön

^*Corresponding author for this work

Clinic of Internal Medicine III - Pulmonology

42 Citations (Scopus)

Abstract

According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5 years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.

Original language	English
Journal	Journal of Internal Medicine
Volume	284
Issue number	2
Pages (from-to)	163-188
Number of pages	26
ISSN	0954-6820
DOIs	https://doi.org/10.1111/joim.12780
Publication status	Published - 08.2018

Funding

M. Hauptmann, J. Heyckendorf, C. Lange, S. Niemann and U. E. Schaible are supported by the German Center for Infection Research (DZIF). The Leibniz Research Campus EvoLung supports M. Hauptmann, S. Niemann and U. E. Schaible. T. Schön and S. Brighenti are supported by the Swedish Research council and the Swedish Heart and Lung Foundation (Oscar II Jubilée Foundation). A. H. Diacon is supported by the South African National Research Foundation.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1111/joim.12780

Cite this

Lange, C., Alghamdi, W. A., Al-Shaer, M. H., Brighenti, S., Diacon, A. H., DiNardo, A. R., Grobbel, H. P., Gröschel, M. I., von Groote-Bidlingmaier, F., Hauptmann, M., Heyckendorf, J., Köhler, N., Kohl, T. A., Merker, M., Niemann, S., Peloquin, C. A., Reimann, M., Schaible, U. E., Schaub, D., ... Schön, T. (2018). Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. Journal of Internal Medicine, 284(2), 163-188. https://doi.org/10.1111/joim.12780

@article{c6589502928d46e9ad7bca7fc3b0c935,

title = "Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis",

abstract = "According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5 years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20\% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.",

author = "C. Lange and Alghamdi, \{W. A.\} and Al-Shaer, \{M. H.\} and S. Brighenti and Diacon, \{A. H.\} and DiNardo, \{A. R.\} and Grobbel, \{H. P.\} and Gr{\"o}schel, \{M. I.\} and \{von Groote-Bidlingmaier\}, F. and M. Hauptmann and J. Heyckendorf and N. K{\"o}hler and Kohl, \{T. A.\} and M. Merker and S. Niemann and Peloquin, \{C. A.\} and M. Reimann and Schaible, \{U. E.\} and D. Schaub and V. Schleusener and T. Thye and T. Sch{\"o}n",

note = "Funding Information: M. Hauptmann, J. Heyckendorf, C. Lange, S. Niemann and U. E. Schaible are supported by the German Center for Infection Research (DZIF). The Leibniz Research Campus EvoLung supports M. Hauptmann, S. Niemann and U. E. Schaible. T. Sch{\"o}n and S. Brighenti are supported by the Swedish Research council and the Swedish Heart and Lung Foundation (Oscar II Jubil{\'e}e Foundation). A. H. Diacon is supported by the South African National Research Foundation. Publisher Copyright: {\textcopyright} 2018 The Association for the Publication of the Journal of Internal Medicine Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2018",

month = aug,

doi = "10.1111/joim.12780",

language = "English",

volume = "284",

pages = "163--188",

journal = "Journal of Internal Medicine",

issn = "0954-6820",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

Lange, C, Alghamdi, WA, Al-Shaer, MH, Brighenti, S, Diacon, AH, DiNardo, AR, Grobbel, HP, Gröschel, MI, von Groote-Bidlingmaier, F, Hauptmann, M, Heyckendorf, J, Köhler, N, Kohl, TA, Merker, M, Niemann, S, Peloquin, CA, Reimann, M, Schaible, UE, Schaub, D, Schleusener, V, Thye, T & Schön, T 2018, 'Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis', Journal of Internal Medicine, vol. 284, no. 2, pp. 163-188. https://doi.org/10.1111/joim.12780

TY - JOUR

T1 - Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis

AU - Lange, C.

AU - Alghamdi, W. A.

AU - Al-Shaer, M. H.

AU - Brighenti, S.

AU - Diacon, A. H.

AU - DiNardo, A. R.

AU - Grobbel, H. P.

AU - Gröschel, M. I.

AU - von Groote-Bidlingmaier, F.

AU - Hauptmann, M.

AU - Heyckendorf, J.

AU - Köhler, N.

AU - Kohl, T. A.

AU - Merker, M.

AU - Niemann, S.

AU - Peloquin, C. A.

AU - Reimann, M.

AU - Schaible, U. E.

AU - Schaub, D.

AU - Schleusener, V.

AU - Thye, T.

AU - Schön, T.

N1 - Funding Information: M. Hauptmann, J. Heyckendorf, C. Lange, S. Niemann and U. E. Schaible are supported by the German Center for Infection Research (DZIF). The Leibniz Research Campus EvoLung supports M. Hauptmann, S. Niemann and U. E. Schaible. T. Schön and S. Brighenti are supported by the Swedish Research council and the Swedish Heart and Lung Foundation (Oscar II Jubilée Foundation). A. H. Diacon is supported by the South African National Research Foundation. Publisher Copyright: © 2018 The Association for the Publication of the Journal of Internal Medicine Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2018/8

Y1 - 2018/8

N2 - According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5 years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.

AB - According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5 years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.

UR - https://www.scopus.com/pages/publications/85050187914

U2 - 10.1111/joim.12780

DO - 10.1111/joim.12780

M3 - Journal articles

AN - SCOPUS:85050187914

SN - 0954-6820

VL - 284

SP - 163

EP - 188

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

IS - 2

ER -

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this